Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 62192.1 IP-LS
• Titre du projet anglais: Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)

Description succincte (Allemand)

Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies (Innolink: 101.651 IP-LS)

Description succincte (Anglais)

Glycopeptides to drive an anti-tumour immune response and improve outcomes in cancer immunotherapies

Résumé des résultats (Abstract) (Allemand)

Most cancer patients do not respond to immunotherapies. Altered glycosylation of tumors is a signature of cancer development, making glycans an emerging target. The project studies glycopeptides as novel therapeutics that steer immune responses to control tumor growth and enhance treatment response.